2-[methyl(pyrimidin-4-yl)amino]ethanol | 340742-86-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-[methyl(pyrimidin-4-yl)amino]ethanol
• 英文别名: Ethanol, 2-(methyl-4-pyrimidinylamino)-
• CAS: 340742-86-1
• 化学式: C₇H₁₁N₃O
• 分子量: 153.184
• InChiKey: SSDGVZGQKQLRKQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  49.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-[(6'-chloropyrimidin-4'-yl)(methylamino)]ethanol 在 钯 作用下， 以 乙醇 、 水 为溶剂， 25.0 ℃ 、810.53 MPa 条件下， 反应 8.0h， 生成 2-[methyl(pyrimidin-4-yl)amino]ethanol
  参考文献：
  名称：

  Thiazolidinedione derivatives as antidiabetic agents

  摘要：

  本发明涉及一般式(I)的化合物，其可能的药学上可接受的盐和互变异构体形式。本发明还涉及一种制备它们的方法，以及它们作为抗糖尿病和降糖剂的用途，单独或与其他抗糖尿病药物（如磺脲类或双胍类药物）结合使用，并用于治疗与胰岛素抵抗有关的并发症，如高血压、高尿酸血症或其他与糖尿病有关的心血管、代谢、内分泌疾病或其他疾病。

  公开号：

  US07001910B1

文献信息

• WO2019238424A5
  申请人：——

  公开号：WO2019238424A5

  公开（公告）日：2022-06-06
• THIAZOLIDINEDIONE DERIVATIVES AS ANTIDIABETIC AGENTS
  申请人：VITA-INVEST, S.A.

  公开号：EP1231211B1

  公开（公告）日：2003-05-28
• NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES
  申请人：GALAPAGOS NV

  公开号：US20220402911A1

  公开（公告）日：2022-12-22

  The present invention discloses compounds according to Formula I: wherein R 1 , R 2a , X, Y, and Z are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformation, diseases involving impairment of bone turnover, diseases associated with hypersecretion of IL-6, diseases associated with hypersecretion of TNFα, interferons, IL-12 and/or IL-23, respiratory diseases, endocrine and/or metabolic diseases, cardiovascular diseases, dermatological diseases, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.
• US7001910B1
  申请人：——

  公开号：US7001910B1

  公开（公告）日：2006-02-21
• [EN] NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES<br/>[FR] NOUVEAUX COMPOSÉS ET COMPOSITIONS PHARMACEUTIQUES ASSOCIÉES POUR LE TRAITEMENT DE MALADIES
  申请人：GALAPAGOS NV

  公开号：WO2019238424A1

  公开（公告）日：2019-12-19

  The present invention discloses compounds according to Formula I: wherein R1, R2a, X, Y, and Z are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformation, diseases involving impairment of bone turnover, diseases associated with hypersecretion of IL-6, diseases associated with hypersecretion of TNFα, interferons, IL-12 and/or IL-23, respiratory diseases, endocrine and/or metabolic diseases, cardiovascular diseases, dermatological diseases, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.